ALSUntangled #71: Nuedexta

Yuyao Sun; Michael Benatar; Javier Mascías Cadavid; Dave Ennist; Paul Wicks; Kim Staats; Morgan Beauchamp; Sartaj Jhooty; Gary Pattee; Andrew Brown; Tulio Bertorini; Paul Barkhaus; Mark Bromberg; Greg Carter; Richard Bedlack; Xiaoyan Li

doi:10.1080/21678421.2023.2239292

ALSUntangled #71: Nuedexta

Yuyao Sun, Michael Benatar, Javier Mascías Cadavid, Dave Ennist, Paul Wicks, Kim Staats, Morgan Beauchamp, Sartaj Jhooty, Gary Pattee, Andrew Brown, Tulio Bertorini, Paul Barkhaus, Mark Bromberg, Greg Carter, Richard Bedlack, Xiaoyan Li

Research output: Contribution to journal › Review article › peer-review

1 Scopus citations

Abstract

Nuedexta is a combination of dextromethorphan hydrobromide and quinidine sulfate and was approved by the Food and Drug Administration (FDA) in 2010 to treat pseudobulbar affect (PBA). There have since been anecdotal case reports of bulbar function improvements after Nuedexta treatment. Here, we review the off-label use of Nuedexta for improving bulbar function in people with ALS. Nuedexta has plausible mechanisms for protecting brain stem motor neurons via its effects on S1R and glutamate excitotoxicity. Recent clinical trials support that Nuedexta can improve bulbar function in PALS, with or without PBA. Nuedexta causes mild to moderate side effects. Based on this information, we support considering Nuedexta treatment for bulbar dysfunction in ALS patients with or without PBA.

Original language	English
Pages (from-to)	218-222
Number of pages	5
Journal	Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Volume	25
Issue number	1-2
DOIs	https://doi.org/10.1080/21678421.2023.2239292
State	Published - 2024
Externally published	Yes

Keywords

ALS
N-Methyl-D-Aspartate receptor (NMDAR)
Nuedexta
dextromethorphan
sigma-1 receptor (S1R)

Access to Document

10.1080/21678421.2023.2239292

Cite this

@article{6670ab48b4f74980829de062dd770658,

title = "ALSUntangled #71: Nuedexta",

abstract = "Nuedexta is a combination of dextromethorphan hydrobromide and quinidine sulfate and was approved by the Food and Drug Administration (FDA) in 2010 to treat pseudobulbar affect (PBA). There have since been anecdotal case reports of bulbar function improvements after Nuedexta treatment. Here, we review the off-label use of Nuedexta for improving bulbar function in people with ALS. Nuedexta has plausible mechanisms for protecting brain stem motor neurons via its effects on S1R and glutamate excitotoxicity. Recent clinical trials support that Nuedexta can improve bulbar function in PALS, with or without PBA. Nuedexta causes mild to moderate side effects. Based on this information, we support considering Nuedexta treatment for bulbar dysfunction in ALS patients with or without PBA.",

keywords = "ALS, N-Methyl-D-Aspartate receptor (NMDAR), Nuedexta, dextromethorphan, sigma-1 receptor (S1R)",

author = "Yuyao Sun and Michael Benatar and {Masc{\'i}as Cadavid}, Javier and Dave Ennist and Paul Wicks and Kim Staats and Morgan Beauchamp and Sartaj Jhooty and Gary Pattee and Andrew Brown and Tulio Bertorini and Paul Barkhaus and Mark Bromberg and Greg Carter and Richard Bedlack and Xiaoyan Li",

note = "Publisher Copyright: {\textcopyright} 2023 World Federation of Neurology on behalf of the Research Group on Motor Neuron Diseases.",

year = "2024",

doi = "10.1080/21678421.2023.2239292",

language = "English",

volume = "25",

pages = "218--222",

journal = "Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration",

issn = "2167-8421",

publisher = "Informa Healthcare",

number = "1-2",

}

TY - JOUR

T1 - ALSUntangled #71

T2 - Nuedexta

AU - Sun, Yuyao

AU - Benatar, Michael

AU - Mascías Cadavid, Javier

AU - Ennist, Dave

AU - Wicks, Paul

AU - Staats, Kim

AU - Beauchamp, Morgan

AU - Jhooty, Sartaj

AU - Pattee, Gary

AU - Brown, Andrew

AU - Bertorini, Tulio

AU - Barkhaus, Paul

AU - Bromberg, Mark

AU - Carter, Greg

AU - Bedlack, Richard

AU - Li, Xiaoyan

PY - 2024

Y1 - 2024

N2 - Nuedexta is a combination of dextromethorphan hydrobromide and quinidine sulfate and was approved by the Food and Drug Administration (FDA) in 2010 to treat pseudobulbar affect (PBA). There have since been anecdotal case reports of bulbar function improvements after Nuedexta treatment. Here, we review the off-label use of Nuedexta for improving bulbar function in people with ALS. Nuedexta has plausible mechanisms for protecting brain stem motor neurons via its effects on S1R and glutamate excitotoxicity. Recent clinical trials support that Nuedexta can improve bulbar function in PALS, with or without PBA. Nuedexta causes mild to moderate side effects. Based on this information, we support considering Nuedexta treatment for bulbar dysfunction in ALS patients with or without PBA.

AB - Nuedexta is a combination of dextromethorphan hydrobromide and quinidine sulfate and was approved by the Food and Drug Administration (FDA) in 2010 to treat pseudobulbar affect (PBA). There have since been anecdotal case reports of bulbar function improvements after Nuedexta treatment. Here, we review the off-label use of Nuedexta for improving bulbar function in people with ALS. Nuedexta has plausible mechanisms for protecting brain stem motor neurons via its effects on S1R and glutamate excitotoxicity. Recent clinical trials support that Nuedexta can improve bulbar function in PALS, with or without PBA. Nuedexta causes mild to moderate side effects. Based on this information, we support considering Nuedexta treatment for bulbar dysfunction in ALS patients with or without PBA.

KW - ALS

KW - N-Methyl-D-Aspartate receptor (NMDAR)

KW - Nuedexta

KW - dextromethorphan

KW - sigma-1 receptor (S1R)

UR - http://www.scopus.com/inward/record.url?scp=85165715762&partnerID=8YFLogxK

U2 - 10.1080/21678421.2023.2239292

DO - 10.1080/21678421.2023.2239292

M3 - Review article

C2 - 37493197

AN - SCOPUS:85165715762

SN - 2167-8421

VL - 25

SP - 218

EP - 222

JO - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

JF - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

IS - 1-2

ER -

ALSUntangled #71: Nuedexta

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this